Comparative analysis of AR variant AR-V567es mRNA detection systems reveals eminent variability and questions the role as a clinical biomarker in prostate cancer.

CONCLUSIONS: Validation of biomarker detection approaches is one of the most critical steps prior to transfer into clinical application. By performing comparative analysis of different detection approaches we revealed eminent variability among previously described systems. Furthermore, we demonstrate an overestimation of AR-V567es in PC, presumably due to non-specific detection of AR-FL mRNA. Therefore, any correlation between AR-V567es expression and clinical responses is highly doubtful and does not reflect the biological nature of the disease.
PMID: 30992298 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 15, 2019 Category: Cancer & Oncology Authors: Bernemann C, Humberg V, Thielen B, Steinestel J, Chen X, Duensing S, Schrader AJ, Boegemann M Tags: Clin Cancer Res Source Type: research